Barclays
GTBP icon

Barclays’s GT Biopharma GTBP Stock Holding History

Barclays’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$706 Buy
+58
New +$588 ﹤0.01% 4963
2022
Q2 		– Sell
-4
Closed -$8K – 5121
2022
Q1 		$8K Buy
+4
New +$8.82K ﹤0.01% 4630

Other funds holding GTBP

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
OWA
Opal Wealth Advisors Jericho, New York $463M AUM 20.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM

Barclays's GTBP Position: Q2 2026 in Review

Barclays opened a new position in GT Biopharma (GTBP) in Q2 2026: 58 shares worth $706. The stake represents ﹤0.01% of the portfolio and ranks #4963 among its holdings. This is a return to the name: Barclays previously reported a position in GTBP as recently as Q1 2022.

Barclays first reported a position in GTBP in Q1 2022 and has held it in 2 quarters since. The position peaked at $8K in Q1 2022. 55 funds tracked by Wall St. Rank hold GTBP as of Q2 2026.

  • Barclays held 58 shares of GT Biopharma worth $706 as of Q2 2026.
  • GT Biopharma was a new Barclays position in Q2 2026.
  • GT Biopharma made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4963 holding.
  • Barclays first reported a position in GT Biopharma in Q1 2022 and has held it in 2 quarters since.
  • Barclays's GT Biopharma position peaked at $8K in Q1 2022.
  • 55 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.